Skip to content
1 min left · finish 11:38 AM
Email
Boston
Meridan ReportBoston: Biotech, AI research, institutional finance
Good morning, Columbus☀️48°F · Clear
BostonTechnologyHealthBusinessMore categoriesCommunitySchoolsGovernmentSportsReal EstateDiningArtsSearchSaved

Advertisement · Why this ad?

  1. Home
  2. /Health
  3. /‘Fancy cars hold no appeal’: My wife and I have a 99% chance of outliving our savings. Why don’t we spend it all?
Health

‘Fancy cars hold no appeal’: My wife and I have a 99% chance of outliving our savings. Why don’t we spend it all?

Marcus Chen
Marcus Chen
Marcus Chen
Managing Editor · St. Paul, MN

Marcus manages the day-to-day editorial workflow across all brands, coordinating coverage assignments and ensuring editorial standards are met. He previously served as city editor at the Pioneer Press and holds a degree in Political Science from Carleton College.

More from Marcus →
Managing Editor · Thursday, October 29, 2026 at 9:15 AM · 1 min read
Text size
Typeface
Line spacing
Theme
Focus mode
Email
‘Fancy cars hold no appeal’: My wife and I have a 99% chance of outliving our savings. Why don’t we spend it all? — Boston Health news

“I’m 68, she’s 74, and we’re both in good health. We married later in life and have no children or close family remaining.”

Up nextThe U.S. government will no longer penalize American companies for making six popular peptidesHealth · 5 min read
#wellness

More Health stories

Pharmacist preparing medications in a compounding pharmacy in New York City
Health

The U.S. government will no longer penalize American companies for making six popular peptides

By Marcus Chen

Hungryroot Coupon Codes: 30% Off This November 2026 — Wired
Health

Hungryroot Coupon Codes: 30% Off This November 2026

By Katherine Langford

Medicare used AI to pre-approve patient care, and it immediately led to a large drop in medical services — MarketWatch
Technology

Medicare used AI to pre-approve patient care, and it immediately led to a large drop in medical services

By Katherine Langford

Lilly raises outlook for third time this year as Zepbound sales soar — MarketWatch
Business

Lilly raises outlook for third time this year as Zepbound sales soar

By Katherine Langford

Also covering Global

Hong KongSeattleAustinWashington DCMiami

Meridan Report — Boston

Part of the Meridan Report Network

Boston: Biotech, AI research, institutional finance. Finance, AI, and technology intelligence across 40 global cities.

Sections

TechnologyHealthBusinessCommunitySchoolsGovernment

Latest Stories

China’s leaders vow tougher corruption crackdownThe Kindle Accessories I Never Want to Read Without (2026)Medicare used AI to pre-approve patient care, and it immediately led to a large drop in medical servicesCathie Wood’s ARK buys the dip on Robinhood in its largest purchase in 6 months after 23% slumpAn AI Breakthrough Has Made Decades of Computer Science Research ‘Irrelevant’

About

Meridan Report delivers institutional-grade intelligence on finance, AI, and technology from 40 global markets.

RSS FeedNetwork Directory

© 2026 Meridan Report — meridanreport.com

PrivacyTerms

A product of Edina Automation LLC

You're offline — showing the last loaded page
HomeSearchSaved